Sangita Choudhury

Sangita Choudhury

Auto-generated profile, based on publicly available information

Sangita Choudhury

Division of Genetics and Genomics, Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, MA (N.H., M.A., S.C.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BPBrian D. Polizzotti
Brian D. Polizzotti
BGBalakrishnan Ganapathy
Balakrishnan Ganapathy
SWStuart Walsh
Stuart Walsh
SCSangita Choudhury
Sangita Choudhury
NANiyatie Ammanamanchi
Niyatie Ammanamanchi
BKBernhard Kühn
Bernhard Kühn
The growth factor neuregulin stimulates heart muscle repair in newborn mice and heart muscle from human infants if given during a specific therapeutic time period.

2 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
TCTim H. H. Coorens
Tim H. H. Coorens
JOJi Won Oh
Ji Won Oh
YCYujin Angelina Choi
Yujin Angelina Choi
NLNam Seop Lim
Nam Seop Lim
BZBoxun Zhao
Boxun Zhao
FVFlora Maria Vaccarino
Flora Maria Vaccarino
From fertilization onwards, the cells of the human body acquire variations in their DNA sequence, known as somatic mutations. These postzygotic mutations arise from intrinsic errors in DNA replication and repair, as well as from exposure to mutagens. Somatic mutations have been implicated in some diseases, but a fundamental understanding of the frequency, type and patterns of mutations across healthy human tissues has been limited. This is primarily due to the small proportion of cells harbouring specific somatic variants within an individual, making them more challenging to detect than inherited variants. Here we describe the Somatic Mosaicism across Human Tissues Network, which aims to create a reference catalogue of somatic mutations and their clonal patterns across 19 different tissue sites from 150 non-diseased donors and develop new technologies and computational tools to detect somatic mutations and assess their phenotypic consequences, including clonal expansions. This strategy enables a comprehensive examination of the mutational landscape across the human body, and provides a comparison baseline for somatic mutation in diseases. This will lead to a deep understanding of somatic mutations and clonal expansions across the lifespan, as well as their roles in health, in ageing and, by comparison, in diseases.

11 August 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
SCSangita Choudhury
Sangita Choudhury
AHAugust Yue Huang
August Yue Huang
JKJunho Kim
Junho Kim
ZZZinan Zhou
Zinan Zhou
KMKatherine Morillo
Katherine Morillo
CWChristopher A. Walsh
Christopher A. Walsh
The accumulation of somatic DNA mutations over time is a hallmark of aging in many dividing and nondividing cells but has not been studied in postmitotic human cardiomyocytes. Using single-cell whole-genome sequencing, we identified and characterized the landscape of somatic single-nucleotide variants (sSNVs) in 56 single cardiomyocytes from 12 individuals (aged from 0.4 to 82 years). Cardiomyocyte sSNVs accumulate with age at rates that are faster than in many dividing cell types and nondividing neurons. Cardiomyocyte sSNVs show distinctive mutational signatures that implicate failed nucleotide excision repair and base excision repair of oxidative DNA damage, and defective mismatch repair. Since age-accumulated sSNVs create many damaging mutations that disrupt gene functions, polyploidization in cardiomyocytes may provide a mechanism of genetic compensation to minimize the complete knockout of essential genes during aging. Age-related accumulation of cardiac mutations provides a paradigm to understand the influence of aging on cardiac dysfunction.

15 January 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MCMing Hui Chen
Ming Hui Chen
SCSangita Choudhury
Sangita Choudhury
MHMami Hirata
Mami Hirata
SKSiri Khalsa
Siri Khalsa
BCBernard Chang
Bernard Chang
CWChristopher A. Walsh
Christopher A. Walsh

9 March 2011 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
SCSangita Choudhury
Sangita Choudhury
SBSoochan Bae
Soochan Bae
QKQingen Ke
Qingen Ke
JLJi Yoo Lee
Ji Yoo Lee
JKJacob Kim
Jacob Kim
Peter KangPeter Kang
Peter Kang

11 May 2011 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
SBSoochan Bae
Soochan Bae
BYBhargavi Yalamarti
Bhargavi Yalamarti
QKQingen Ke
Qingen Ke
SCSangita Choudhury
Sangita Choudhury
HYHyeon Yu
Hyeon Yu
Peter KangPeter Kang
Peter Kang
Vitamin D deficiency is associated with cardiac hypertrophy and heart failure, and vitamin D therapy prevents the progression of cardiac hypertrophy in animal models. Here, we examine whether vitamin D therapy prevents progression of pre-existing cardiac hypertrophy and development of heart failure. When male Dahl salt-sensitive rats were fed a high salt (HS) diet, all rats developed cardiac hypertrophy after 5 weeks. Thereafter, rats were treated with vehicle (V), paricalcitol (PC, an active vitamin D analogue, at 200 ng, IP 3x/week), enalapril (EP, 90 μg/day), and PC + EP. All groups were continued on the HS diet and evaluated after 4 weeks of therapy. The PC and PC + EP groups, but not the V and EP only groups, showed significant prevention of progression of pre-existing cardiac hypertrophy. The signs of decompensated heart failure were evident in the vehicle-treated group; these heart failure parameters significantly improved with PC, EP or PC + EP therapy. The expression of PKCα, which is regulated by Ca2+and known to stimulate cardiac hypertrophy, was significantly increased in the vehicle group, and PC, EP or PC + EP effectively decreased PKCα activation. We also observed normalization of genetic alterations during progression to heart failure with PC treatment. PC treatment resulted in both the prevention of progression of pre-existing cardiac hypertrophy and the development of heart failure, compared with improvement in progression to heart failure by EP alone. These beneficial findings in heart were associated with inhibition of PKCα activation and reversal of gene alterations.